

Index

A

- ABMT. See Autologous bone marrow transplant
- Accreditation. See Quality control and accreditation
- AIDS
 - expenditures for new treatments, 281, 282
 - new drug approvals, 26
 - zidovudine treatment, 38
- American Journal of Surgery*, 125
- Antenatal fetal heart rate monitoring, 36
- Antilymphocyte serum
 - kidney transplants and, 10
- Applied research. See *also* Research and development policy and, 2
- Arteriovenous malformations, 37-38
- Arthroscopic surgery
 - France, 124
 - MRI comparison, 7
 - United Kingdom, 263
- Artificial heart
 - United States, 292
- Atherectomy, for coronary artery disease, 41
- Australia. See *also* International comparisons
 - Adverse Drug Reactions Advisory Committee, 25
 - Australia and New Zealand Dialysis and Transplant Registry, 47
 - Bureau of Statistics, 20, 23
 - Cardiac Society of Australia and New Zealand PTCA guidelines, 40
 - Care Evaluation Program, 28-29
 - case studies
 - breast cancer screening, 51-53
 - coronary artery disease, 39-41
 - end-stage renal disease, 47-49
 - Laparoscopic surgery, 44-47
 - medical imaging (CT and MR1), 42-44
 - neonatal intensive care, 49-51
 - Casemix Development Program, 24-25
 - Committee on Applications and Costs of Modern Technology in Medical Practice, 29
 - cooperative research centers, 23
 - Coordination Committee on Organ Registries and Donation, 48
 - Council on Health Care Standards, 28
 - Customs (Prohibited Imports) Regulations, 25
 - Department of Human Services and Health, 22, 23,35
 - Drug Evaluation Committee, 25
 - economy, 20
 - Federal National Health Act, 29
 - government and political structure, 19-20
 - health care system
 - health expenditures and health services, 23-24
 - medical research and policy coordination, 23
 - organization and funding, 21-22
 - pharmaceutical benefitsj24
 - proposals for change, 24-25
 - health care technology assessment
 - agencies, 30
 - current structure of assessment entities, 32-33
 - description, 29-30
 - funding, 34-35
 - highly specialized drugs, 38
 - impacts, 35-37
 - national advisory bodies, 30-32
 - nationally funded centers, 33, 37-38
 - health care technology controls
 - financial controls for health care technology, 27-28
 - medical devices, 26-27
 - pharmaceuticals regulation, 25-26
 - placement of services, 28
 - quality control and accreditation, 28-29
 - Health Ministers' Advisory Council, 23,34
 - extracorporeal membrane oxygenation, 50-51
 - Health Ministers' Conference, 23
 - health status of population, 20-21
 - health expenditures and health services, 22, 23-24
 - Health Technology Advisory Committee
 - end-stage renal disease guidelines, 47-48
 - formulation and operation of, 30,31,32-33, 34,35,36,37
 - Highly Specialized Drugs Working Party, 38
 - hospital accreditation, 28

356 Health Care Technology and Its Assessment in Eight Countries

infant mortality rate, 3
Institute of Health and Welfare, 23,34-35,36
laparoscopy cost effectiveness, 9
life expectancy, 4
major health concerns, 21
Medical Benefits Schedule, 22,27
National Association of Testing Authorities, 29
National Breast Cancer Screening Evaluation, 51
National Center for Health Program Evaluation, 33
National Health and Medical Research Council, 23,32,33,36
 CT recommendations, 42-43
 extracorporeal membrane oxygenation, 50-51
 mammography policy, 53
 MRI recommendations, 43-44
National Health Technology Advisory Panel, 30-32,34,35,36,37,343
National Pathology Accreditation Advisory Council, 29
National Program for the Detection of Breast Cancer, 52
New Drug Formulation, 25
pathology laboratory accreditation, 29
Pharmaceutical Benefits Advisory Committee, 26
Pharmaceutical Benefits Scheme, 22,24
population, GDP per capita, and health care spending, 2, 3
population characteristics, 19
State Health (Radiation Safety) Act, 28
summary, 53-55
Superspecialty Services Subcommittee, 30,32, 38
 neonatal intensive care guidelines, 49, 51
Therapeutic Devices Evaluation Committee, 26-27
Therapeutic Goods Act, 25,26
women's health, 21
Autologous bone marrow transplant
 United States, 301-302
Auvard incubators, 11
AVMS. See Arteriovenous malformations
AZT. See Zidovudine

B

Back pain
 Swedish study, 223
Basic research. See *also* Research and development policy and, 2
Benign prostatic hypertrophy
 United States, 296-297
Breast cancer screening
 Australia, 51-53
 Canada, 92-94

economic aspects, 52
France, 131-132
Germany, 164-165
HIP study, 12-13,234,322
international comparisons, 352
Netherlands, 203-205
procedures used, 13
Sweden, 233-234
United Kingdom, 269-270
United States, 321-323

C

CABG. See Coronary artery bypass grafting
CAD. See Coronary artery disease
Canada. See *also* International comparisons
 Bill C-22, 70
 British Columbia
 Office of Health Technology Assessment, 77
 British North America Act of 1867,61
 Bureau of Radiation and Medical Devices,71
 Canadian Coordinating Office for Health Technology Assessment, 77,93
 research budget, 69
 Canadian EPO Group, 11
 Canadian Medical Association, 78
 Canadian Organ Replacement Registry, 88
 Canadian Task Force on the Periodic Health Examination, 75-76,78
case studies
 breast cancer screening, 92-94
 coronary artery disease, 79-82
 end-stage renal disease, 88-90
 laparoscopic surgery, 9,86-87
 medical imaging (CT and MRI), 82-85
 neonatal intensive care, 12,90-92
Conseil Consultatif de Pharmacologic, 70
Conseil devaluation des Technologies de la Sant6, 69
Constitution Act, 62
economy, 63
Food and Drug Act, 69-70
government and political structure, 61-63
Health and Welfare Canada, 71
 Health Protection Branch, 70,71
health care system
 geographic maldistribution of physicians, 66
 history, 64-65
 number of physicians, 66, 72-73
 Quebec, 66-67
 universal health insurance, 65-66
health care technology assessment, 75-78
health care technology controls
 authorized drugs and prices, 70-71
 control mechanisms control efficacy, 74-75

- cost control efficacy, 74
- equal access to services, 74-75
- health care providers control, 72-73
- macro-mechanisms for fiscal management, 67-68
- marketing authorization and patent protection, 69-70
- medical equipment control, 71-72
- pharmaceuticals control, 69-71
- placement of services, 72
- provider locations control, 74
- recent policy reports and decisions, 68
- research funding, 68-69
- health status of the population, 64
- infant mortality rate, 3
- language and ethnicity issues, 63
- life expectancy, 4
- National Breast Cancer Study, 323
- National Breast Screening Study, 92-93
- National Partnership for Quality in Health, 78
- Ontario
 - Center for Health Economics and Policy Analysis, 77
 - computed tomography, 83-84
 - Institute for Clinical Evaluative Sciences, 77
 - Ontario Medical Association, 77
- Patented Medicine Prices Review Board, 70
- physical description, 61
- political parties, 62-63
- population, GDP per capita, and health care spending, 2, 3, 74
- population characteristics, 63
- provincial populations, 62
- Quebec
 - background, 63-64
 - cardiac services, 79-82
 - Centres Locaux de Services Communautaires, 66
 - Commission of Inquiry on Health and Social Services, 68
 - computed tomography, 84
 - Conseil devaluation des Technologies de la Sante', 68, 74,76-77,91-92,93-94
 - end-stage renal disease, 88, 89-90
 - erythropoietin, 89-90
 - extracorporeal membrane oxygenation, 90-92
 - health care provider control, 72-73
 - health care system, 66-67
 - hospital budgets, 67,74
 - kidney transplants, 89
 - magnetic resonance imaging, 85
 - Ministry of Health and Social Services, 71-72, 73
 - placement of services, 72
 - provider location control, 74
 - Re'gionale de la Sante' et des Services Sociaux, 66-67
 - resource limitations, 75
 - ultrasound, 75
 - summary, 95-96
 - thermography use, 73
 - university-based training programs, 77-78
- Canadian Journal of Surgery*, 86
- Canadian Medical Association Journal*, 76
- Case studies
 - breast cancer screening
 - Australia, 51-53
 - Canada, 92-94
 - France, 131-132
 - Germany, 164-165
 - international comparisons, 345, 352
 - Netherlands, 203-205
 - Sweden, 233-234
 - United States, 321-323
 - coronary artery disease, 4-6
 - Australia, 39-41
 - Canada, 79-82
 - France, 120-122
 - Germany, 154-155
 - international comparisons, 344-345
 - Netherlands, 188-191
 - Sweden, 225-227
 - United States, 304-307
 - end-stage renal disease, 9-11
 - Australia, 47-49
 - Canada, 88-90
 - France, 126-129
 - Germany, 160-162
 - international comparisons, 345, 350-351
 - Netherlands, 198-201
 - Sweden, 231-232
 - United States, 315-318
 - laparoscopic surgery, 8-9
 - Australia, 44-47
 - Canada, 86-87
 - France, 124-126
 - Germany, 158-160
 - international comparisons, 345, 349-350
 - Netherlands, 197-198
 - Sweden, 229-231
 - United States, 311-315
 - medical imaging (CT and MRI), 6-8
 - Australia, 42-44
 - Canada, 82-85
 - France, 122-124
 - Germany, 155-158
 - international comparisons, 345, 348-349
 - Netherlands, 191-197
 - Sweden, 227-229
 - United States, 307-311

358 Health Care Technology and Its Assessment in Eight Countries

- neonatal intensive care, 11-13
 - Australia, 49-51
 - Canada, 90-92
 - France, 129-131
 - Germany, 162-164
 - international comparisons, 345, 351-352
 - Netherlands, 201-203
 - Sweden, 232-233
 - United States, 318-321
 - Cataract surgery
 - United States, 295-296
 - Cerebrovascular embolization, 37-38
 - Clinical investigation and testing. *See also* Research and development policy and, 2
 - Clinton, President Bill
 - health care reform proposal, 279-280
 - Coelioscopy. *See* Laparoscopic surgery
 - Computed tomography
 - Australia, 42-43
 - Canada, 82-84,85
 - France, 112, 122-124
 - Germany, 155-157, 159
 - history of, 6
 - international comparisons, 345, 348-349
 - MRI comparison, 6-8
 - Netherlands, 191-193, 196
 - Sweden, 227-228
 - United Kingdom, 260-261
 - United States, 307-308
 - Congenital diaphragmatic hernias, 91
 - Consensus conferences, 224,259,284-285,299, 305,322
 - Continuous positive airway pressure
 - Sweden, 233
 - United States, 319
 - Coronary artery bypass grafting
 - Australia, 39
 - Canada, 79,81
 - France, 120
 - Germany, 154, 155
 - history of, 4-5
 - Netherlands, 188-190
 - Sweden, 223
 - United Kingdom, 258-259
 - United States, 304,305-306, 307
 - Coronary artery disease, 259
 - coronary artery bypass grafting, 4-5, 6
 - Australia, 39
 - Canada, 79,81
 - France, 120
 - Germany, 154, 155
 - Netherlands, 188-190
 - Sweden, 225-227
 - United Kingdom, 258-259
 - United States, 304, 305-306, 307
 - extracorporeal blood circulation
 - France, 121
 - international comparisons, 344-345
 - percutaneous balloon valvuloplasty
 - Germany, 154
 - percutaneous transluminal coronary angioplasty, 5
 - Australia, 39-41
 - Canada, 79-80
 - France, 120-122
 - Germany, 154, 155
 - Netherlands, 190-191
 - Sweden, 226-227
 - United Kingdom, 260
 - United States, 304,305-307
 - restenosis rate, 121, 226
 - Vineberg procedure, 304
 - Coronary stents, 41
 - CT. *See* Computed tomography
 - Cyclosporine, 10,38, 127
- ### D
- D&C. *See* Dilatation and curettage
 - DeBakey, Michael, 4
 - Defensive medicine, 279
 - Desferoxamine, 38
 - Diabetic nephropathy
 - end-stage renal disease and, 47
 - Dialysis. *See* Hemodialysis
 - Didanosine, 38
 - Diffusion. *See also specific technologies by name*
 - definition, 2
 - policy and, 2-3
 - Dilatation and curettage, 44-45
 - Dotter and Judkins
 - catheter use in coronary artery disease, 4-5
 - Drugs. *See* Pharmaceutical regulation
- ### E
- EBC. *See* Extracorporeal blood circulation
 - ECMO. *See* Extracorporeal membrane oxygenation
 - End-stage renal disease
 - erythropoietin, 10-11
 - Australia, 48
 - Canada, 89-90
 - France, 128
 - Germany, 162
 - Netherlands, 201
 - Sweden, 232
 - United Kingdom, 266-267
 - United States, 317-318
 - hemodialysis, 9, 10
 - Australia, 47
 - Canada, 88

- France, 127
 - Germany, 160-161
 - Netherlands, 198-201
 - Sweden, 231
 - United Kingdom, 265-266
 - United States, 315,316
 - international comparisons, 350-351
 - kidney transplants, 9-10
 - Australia, 47-48
 - Canada, 88-89
 - France, 127-128
 - Germany, 161-162
 - Netherlands, 198-201
 - Sweden, 231
 - United Kingdom, 264-265
 - United States, 315-317
 - Endoscopy. See *also* Laparoscopic surgery
 - history of, 8
 - EPO. See Erythropoietin
 - Erythropoietin, 10-11
 - Australia, 48
 - Canada, 89-90
 - France, 128
 - Germany, 162
 - highly specialized drug listing, 38
 - Netherlands, 201
 - Sweden, 232
 - United Kingdom, 266-267
 - United States, 317-318
 - ESRD. See End-stage renal disease
 - ESWL. See Extracorporeal shock wave lithotripsy
 - Eurotransplant, 199
 - Evans and colleagues
 - quality of life and EPO, 11
 - Excimer laser angioplasty, 5, 41
 - Extracorporeal blood circulation
 - France, 121
 - Extracorporeal membrane oxygenation, 12
 - Australia, 50-51
 - Canada, 90-92
 - France, 130-131
 - Germany, 163
 - Netherlands, 203
 - Sweden, 233
 - United Kingdom, 269
 - United States, 320-321
 - Extracorporeal shock wave lithotripsy
 - Canada, 87
 - Netherlands, 197
- F**
- Framingham Heart Study, 306
 - France. See *also* International comparisons
 - Agency for the Development of Medical Evaluation, 109, 115-117, 118
 - case studies
 - breast cancer screening, 131-132
 - coronary artery disease, 120-122
 - end-stage renal disease, 126-129
 - laparoscopic surgery, 124-126
 - medical imaging (CT and MRI), 122-124
 - neonatal intensive care, 129-131
 - causes of death, 104
 - Centre National de l'Equipment Hospitalier, 119
 - Committee for Evaluation and Diffusion of Medical Technology, 114, 115, 116
 - France Transplant, 128
 - French Society for Evaluation in Health Care and Technology Assessment, 119
 - government and political structure, 103-104
 - health care system
 - general administration, 105-107
 - health map, 105, 112-113
 - hospital system, 106-107, 109-110
 - number of physicians, 107
 - payment for health care, 107-110
 - price setting, 108-110
 - private office practice, 109
 - social security system, 107-108
 - health care technology assessment
 - agencies involved, 114-117
 - CNAMTS medical board, 120
 - evaluation bureau of the department of hospitals, 118-119
 - law on hospitalization, 117-119
 - medical school departments of public health, 119-120
 - physicians, 119
 - private consultants, 119
 - researchers, 119
 - health care technology controls
 - health care planning, 112-114
 - pharmaceuticals regulation, 110-112
 - post-marketing quality control, 111-112
 - pre-marketing approval process, 111
 - health-related expenditures, 105
 - health status of the population, 104-105
 - infant mortality rate, 3
 - infectious disease incidence, 105
 - Institut National de la Santé de la Recherche Medicale
 - medical practitioners report, 107
 - life expectancy, 4
 - National Sickness Fund, 108, 109, 119, 120
 - breast cancer prevention program, 132
 - Neonatal Study Group, 129, 130

360 Health Care Technology and Its Assessment in Eight Countries

population, GDP per capita, and health care spending, 2, 3
population characteristics, 104-105
Regional Committees for Medical Evaluation of Hospitals, 117-118
regional scheme of health organization, 112-113
Social Aid Scheme, 105, 108
summary, 132-133

G

Gallbladder removal. See Laparoscopic surgery, cholecystectomy
Gamete intrafallopian transfer, 49-50
Ganciclovir, 38
Germany. See *also* International comparisons
birth rate decline, 138
Board of Experts for the Concerted Action in Health Care, 140, 153, 161
Buro fur Technikfolgenabschätzung beim Deutschen Bundestag, 148
case studies
breast cancer screening, 164-165
coronary artery disease, 154-155
end-stage renal disease, 160-162
laparoscopic surgery, 8, 158-160
medical imaging (CT and MRI), 155-158
neonatal intensive care, 162-164
Central Association of Electromedical Industry, 143
Concerted Action in Health Care, 139-140
cost containment debate, 144-147
Department of Research and Technology, 148
deregulation issue, 145
Deutsche Mammographie-Studie, 165
Dialyse Trainingszentren, 161
Drug Law of 1976, 149-150
Einbecker Empfehlung guidelines, 163-164
European Dialysis and Transplant Association, 162
Federal Association of Sickness Fund Doctors, 152
Federal Chamber of Physicians, 164
Federal Commission of Physicians and Mandatory Sickness Funds, 165
Federal Ministry of Research and Technology, 157-158, 165
German Center for Cancer Research, 155
German Society for Thoracic and Cardiovascular Surgery, 155
German Society of Medical Law, 163
Health Care Act of 1992, 145-147, 151, 153
health care system
associations of sickness fund doctors, 141
health care delivery, 140-142

institutional separation of inpatient and outpatient care, 140-142, 151
legislation and financing, 139-140
medical equipment market, 143-144
office-based physicians, 141, 143, 146, 152
private insurance companies, 140
sickness funds, 140, 143, 144-145, 148-149
health care technology assessment, 147-149
health care technology controls
drug price regulation, 150
drug regulation, 149-150
medical device regulation, 150-151
health status of the population, 138-139
Hospital Financing Act of 1972, 142
industrial decline, 138
infant mortality rate, 3
Kuratorium fur Heimdialyse, 160
life expectancy, 4, 138
overview, 137-138
Patienten-Heimversorgung, 161
placement of services, 151-153
population, GDP per capita, and health care spending, 2, 3
quality assurance, 153-154
rate stabilization, 144-145
Regional Associations of Sickness Fund Doctors, 152, 156
Scientific Institute of the Federal Association of Local Sickness Funds, 148
Gruentzig and colleagues
catheter use in coronary artery disease, 5
Gynecological laparoscopic surgery
France, 124-125

H

Health care expenditures
Australia, 23-24
by country, 2,3
France, 105
United Kingdom, 242
United States, 278-279
Health care providers
number of physicians
Canada, 66,72-73
France, 107
Sweden, 220
United States, 277
Health care systems
Australia, 21-25
Canada, 64-67
France, 105-110
Germany, 139-144
Netherlands, 173-178
Sweden, 213-219

- United Kingdom, 243-249
 - United States, 276-280
 - Health care technology assessment. *See also* Health care technology controls
 - Australia, 29-38
 - Canada, 75-78
 - France, 114-120
 - Germany, 147-149
 - Netherlands, 183-187
 - Sweden, 222-225
 - United Kingdom, 256-257
 - United States, 291-304
 - Health care technology controls. *See also* Health care technology assessment
 - Australia, 25-29
 - Canada, 67-75
 - France, 110-114
 - Germany, 147-151
 - Netherlands, 178-183
 - Sweden, 219-222
 - United Kingdom, 249-256
 - United States, 281-291
 - Health Insurance Commission
 - Medicare program administration (United States), 22
 - Health Insurance Plan of Greater New York
 - breast cancer screening study, 12-13,322
 - mammography randomized, controlled trial, 234
 - Health status of the population
 - Australia, 20-21
 - Canada, 64
 - France, 104-105
 - Germany, 138-139
 - Netherlands, 173
 - Sweden, 211-213
 - United Kingdom, 242-243
 - United States, 276
 - Heart transplants
 - Netherlands, 184
 - Hemodialysis, 9, 10
 - Australia, 47
 - Canada, 88
 - France, 127
 - Germany, 160-161
 - Netherlands, 198-201
 - Sweden, 231
 - United Kingdom, 265-266
 - United States, 315,316
 - HIC. *See* Health Insurance Commission
 - High-frequency oscillation ventilation systems
 - Sweden, 233
 - HIP. *See* Health Insurance Plan of Greater New York
 - Hip replacement
 - consensus conferences, 224
 - Home uterine monitors
 - United States, 284,301
 - Hospitals. *See also* Neonatal intensive care; Placement of services
 - Australia, 20,24,28
 - Canada, 67,74
 - France, 106, 109-110, 117-119
 - Germany
 - Health Care Act of 1992, 147
 - hospital ownership types, 141-142
 - institutional separation of inpatient and outpatient care, 140-142, 151
 - quality assurance, 153-154
 - Netherlands, 174, 175-176
 - Article 18 regulation, 181-182
 - Sweden, 216-217,232
 - United Kingdom, 247
 - United States, 277,302
 - Hypertension
 - Swedish study, 223
 - Hysteroscopy, 44-45,47
- I
- Immunosuppressive therapy
 - kidney transplant and, 10,89, 127-128,317
 - In vitro fertilization, 49-50
 - Netherlands, 184
 - Incubators, 11
 - Infant mortality rates
 - Canada, 64
 - by country, 3
 - Sweden, 211
 - United Kingdom, 242
 - United States, 318
 - Infants. *See* Neonatal intensive care
 - International comparisons
 - case studies, 344, 345
 - breast cancer screening, 345,352
 - coronary artery disease, 344-345
 - end-stage renal disease, 345, 350-351
 - laparoscopic surgery, 345,349-350
 - medical imaging (CT and MRI), 345, 348-349
 - neonatal intensive care, 345, 351-352
 - health care technology assessment, 343-344
 - health systems, 335-336,340-341
 - impact of technology assessment on policymaking, 352-353
 - public reactions and pressures, 339,341-342
 - technology adoption, 336-338
 - technology utilization, 338-339
 - International Journal of Technology Assessment in Health Care*, 7
 - International Symposium of Gynecological Endoscopy, 8

362 Health Care Technology and Its Assessment in Eight Countries

K

- Kidney transplants, 9-10
 - Australia, 47-48
 - Canada, 88-89
 - France, 127-128
 - Germany, 161-162
 - Netherlands, 198-201
 - Sweden, 231
 - United Kingdom, 264-265
 - United States, 315-317

L

- Laboratories
 - accreditation, 29
- LAH. See Laparoscopically assisted vaginal hysterectomy
- Laparoscopic surgery
 - appendectomy, 8, 46
 - France, 124, 125
 - Germany, 160
 - Netherlands, 197
 - United Kingdom, 263
 - United States, 314
 - cholecystectomy, 8-9
 - Australia, 45-46,47
 - Canada, 86-87
 - France, 125, 126
 - Germany, 158
 - Netherlands, 197
 - Sweden, 230
 - United Kingdom, 262,263
 - United States, 311-314
 - cost effectiveness, 9, 230
 - digestive surgery
 - France, 125-126
 - gynecological laparoscopy
 - Sweden, 229,230
 - United Kingdom, 263
 - hemiorrhaphy
 - Australia, 46
 - United States, 314
 - history of, 8
 - international comparisons, 349-350
 - percutaneous nephrolithotomy
 - Germany, 158, 160
 - Netherlands, 197
 - uses for, 8-9, 44-45, 314
 - vagotomy
 - Australia, 46-47
- Laparoscopically assisted vaginal hysterectomy, 46
- Laser catheters
 - United States, 284
- Laser treatment for coronary artery disease, 5,41
- Life expectancy

- Australia, 20
- by country, 4
- Germany, 138
- Lion incubators, 11
- Liver transplants
 - Australia, 38
 - Netherlands, 184

M

- Magnetic resonance imaging
 - advantages of, 6-7
 - Australia, 43-44
 - Canada, 84-85
 - costs, 7-8
 - CT comparison, 6-8
 - dry chemistry pathology analyzers, 30,35
 - France, 112, 122-124
 - Germany, 157-158, 159
 - history of, 6
 - international comparisons, 348-349
 - mobile units, 311
 - Netherlands, 193-197
 - pathology testing, 35
 - Sweden, 228-229
 - United Kingdom, 261-262
 - United States, 276,308-311
- Mammography. See Breast cancer screening
- Meconium aspiration syndrome, 50
- Medawar, Peter, 10
- Medical devices and equipment
 - Australia, 26-27
 - Canada, 71-72
 - France, 111-112
 - Germany, 143-144, 150-151
 - Netherlands, 180
 - Sweden, 221-222
 - United Kingdom, 253-254
 - United States, 281,283-285,288,292
- Medical equipment. See Medical devices and equipment
- Medical imaging. See Computed tomography; Magnetic resonance imaging; Positron emission tomography; Sonography; Thermography; Ultrasound; X-ray imaging
- Medical personnel. See Health care providers
- Mental health technology
 - Sweden, 224
- 6-mercaptopurine
 - kidney transplant and, 10
- Minimally invasive surgery. See *also* Laparoscopic surgery
 - in Germany, 158-160
- Minimally invasive therapy. See *also* Laparoscopic surgery

- Sweden, 230
 - MIS. See Minimally invasive surgery
 - MIT. See Minimally invasive therapy
 - Mortality
 - Canada, 64
 - France, 104
 - Netherlands, 174
 - Sweden, 211,213
 - United Kingdom, 242
 - United States, 276
 - MRI. See Magnetic resonance imaging
- N**
- Neonatal intensive care
 - Australia, 49-51
 - Canada, 90-92
 - continuous positive airway pressure, 233, 319
 - extracorporeal membrane oxygenation, 12
 - Australia, 50-51
 - Canada, 90-92
 - France, 130-131
 - Germany, 163
 - Netherlands, 203
 - Sweden, 233
 - United Kingdom, 269
 - United States, 320-321
 - France, 129-131
 - Germany, 162-164
 - high-frequency oscillation ventilation systems, 233
 - history of, 11
 - infant mortality rates and, 11-12
 - international comparisons, 351-352
 - Netherlands, 201-203
 - nitric oxide
 - United States, 320,321
 - surfactants
 - United States, 319-320
 - Sweden, 232-233
 - United Kingdom, 267-269
 - United States, 318-321
 - Netherlands. See *also* International comparisons
 - aging of the population, 173
 - Article 18 of the Hospitals Act, 181-182, 189, 200,202
 - Board for the Evaluation of Drugs, 179
 - case studies
 - breast cancer screening, 203-205
 - coronary artery disease, 188-191
 - end-stage renal disease, 198-201
 - laparoscopic surgery, 197-198
 - medical imaging (CT and MRI), 191-197
 - neonatal intensive care, 12, 201-203
 - causes of death, 174
 - Central Board for Hospital Provisions, 192
 - Central Board of Health Care Tariffs, 176, 177
 - central government
 - technology assessment involvement, 186
 - Committee for the Regulation of Blood and Blood Products, 180
 - Council for Health Research, 179, 187
 - Drugs Act of 1963, 179
 - Dutch Association of Dialysis Doctors, 199,201
 - Dutch Heart Patient Association, 188
 - Dutch Kidney Foundation, 183, 199
 - Dutch Organization for Scientific Research, 179
 - Dutch Pediatric Association, 201
 - economy, 172-173
 - Exceptional Medical Expenses Fund, 204
 - excimer laser angioplasty, 5
 - government structure, 171-172
 - Health 2000 program, 174-175
 - health care system
 - administering the system, 176-177
 - certification of health professionals, 176
 - health care costs, 175-176
 - health insurance, 175
 - history, 173-175
 - legal and legislative background, 175-176
 - regulation of institutions, 175
 - reimbursement of services, 177
 - health care technology assessment
 - development of interest, 183-184
 - heart transplant project, 184
 - liver transplant project, 184
 - national fund for, 184-185
 - new policies, 185-186
 - organizations, 186-187
 - in vitro fertilization project, 184
 - health care technology controls
 - influence of the public, 183
 - medical device regulation, 180
 - payment system and, 182-183
 - planning and regulation of medical services, 180-183
 - regulation of drugs and biological substances, 179-180
 - research and development efforts, 178-179
 - Health Council
 - breast cancer screening, 204
 - CT scanning report, 191-192
 - dialysis and kidney transplant report, 200
 - Medical Practice at the Crossroads*, 185
 - MRI report, 194
 - neonatal intensive care report, 201-202
 - technology assessment involvement, 186
 - health status of the population, 173
 - Hospital Planning Board, 181

364 Health Care Technology and Its Assessment in Eight Countries

- Hospital Provisions Act, 174, 175, 181
Hospital Tariffs Act, 174, 175-176
infant mortality rate, 3
Institute for Medical Technology Assessment
 breast cancer screening, 204-205
 kidney transplant cost effectiveness, 10
life expectancy, 4
Medical Devices Act, 180
Medical Professions Bill, 176
Memorandum on the Structure of Health Care, 174
National Coordination Committee, 204
National Council for Health Care, 186
National Fund for Investigational Medicine, 184-185
National Health Care Board, 204
National Institute for Health and Environmental Hygiene, 187
National Organization for Quality Assurance, 204
National Organization for Quality Assurance in Hospitals, 187
National Registry for Renal Replacement Therapy, 200
National Society of Private Health Care Insurers, 175
Netherlands Organization for Applied Scientific Research, 178, 180, 187
Nieveen Committee, 188
population, GDP per capita, and health care spending, 2, 3
Radiological Society of North America, 191
reform proposals and implementation, 177-178
Renal Patients Association, 199
Royal Dutch Academy of Sciences, 179
Sick Fund Act, 175
Sick Funds Council, 175
 benefit package, 182-183, 184, 186
 breast cancer screening, 204
 erythropoietin negotiations, 201
 guidelines for drug use, 180
 technology assessment involvement, 186
Society of Dutch Sick Funds, 175
Standing Committee on Investigational Medicine, 185
Steering Committee on Future Health Scenarios, 184, 187
summary
 changing policies for controlling health technology, 207
 success of control mechanisms, 206-207
 ways to control health care technology, 205-206
University Institutes for Technology Assessment, 187
NICUS. See Neonatal intensive care
Nordic Evaluation of Medical Technology, 225
 radiology evaluation, 229
- P**
Pancreas transplants, 48
Peptic ulcer disease
 consensus conference recommendations, 284-285
 role of *Helicobacter pylori*, 284-285, 300
Percutaneous balloon valvuloplasty
 Germany, 154
Percutaneous nephrolithotomy
 Netherlands, 197
Percutaneous transluminal coronary angioplasty, 5
 Australia, 39-41
 Canada, 79-80
 France, 120-122
 Germany, 154, 155
 Netherlands, 190-191
 Sweden, 226-227
 United Kingdom, 260
 United States, 304, 305-307
Persistent pulmonary hypertension of the newborn, 91
PET. See Positron emission tomography
Pharmaceutical Manufacturers Association of Canada, 70
Pharmaceutical regulation
 Australia, 25-26, 38
 Canada, 69-71
 drug evaluation, 26
 France, 110-112
 Germany, 149-150
 Netherlands, 179-180
 Sweden, 221
 United Kingdom, 250-253
 United States, 281-283
Philips Medical Electronics, 195-196
Philips Medical Systems, 192, 193-194
Placement of services
 Australia, 28
 Canada, 72
 Germany, 151-153
 United Kingdom, 254-255
Positron emission tomography
 Australia, 44
Preoperative investigations in elective surgery
 Swedish study, 223
PTCA. See Percutaneous transluminal coronary angioplasty

Q

- QALYs. See Quality adjusted life years
 Quality adjusted life years
 coronary artery bypass grafting, 6, 259
 hemodialysis and kidney transplant comparison, 10
 neonatal intensive care, 12
 Quality control and accreditation
 Australia, 28-29
 Germany, 153-154

R

- Radiation treatment of cancer
 Swedish study, 223
 RAND Corp.
 “appropriateness” guidelines, 306, 307
 coronary artery bypass grafting study, 223, 227, 306,307
 PTCA and CABG cost comparison, 5
 Renal transplants. See Kidney transplants
 Research and development
 Australia, 23
 Canada, 68-69
 France, 119
 Netherlands, 178-179
 Sweden, 219-220
 United States, 280-281

S

- Service accessibility. See also Placement of services
 Canada, 74-75
 Silicone breast implants
 United States, 284
 Sonography
 Germany, 155
 Steroidal hormones
 kidney transplants and, 10
 Survival rates
 kidney transplants, 10,89
 Sweden. See also International comparisons
 breast cancer screening studies, 13
 case studies
 breast cancer screening, 233-234
 coronary artery disease, 225-227
 end-stage renal disease, 231-232
 laparoscopic surgery, 229-231
 medical imaging (CT and MRI), 227-229
 neonatal intensive care, 232-233
 causes of death, 211, 213
 Center for Technology Assessment, 225
 Chemical Inspection, 215
 Council of Research, 220
 ecmomy. 209-210

- Federation of County Councils,214,215
 MRI moratorium, 229
 government and political system, 210-211
 Health and Medical Services Act of 1983, 214-215
 health care system
 administration, 215
 co-payment for services, 216
 constitutional basis and legislative background, 213-215
 costs of health care, 216
 financing, 215-216
 number of physicians, 220
 organizational levels, 216-217
 private health care, 213
 public policy concerns, 217-218
 reform proposals and implementation, 218-219
 role of public, 219
 health care technology assessment
 agencies, 222-225
 consensus conferences, 224
 health care technology controls
 medical devices regulation, 221-222
 medical education and employment policies, 220-221
 pharmaceuticals regulation and control, 221
 primary health care payment, 222
 research policies, 219-220
 health status of the population
 relative disease burden, 211, 212
 infant mortality, 3, 211
 Institute of Forensic Medicine, 215
 life expectancy, 4
medical education, 214
Medical Products Agency, 215
 Medical Research Council, 224
 extracorporeal membrane oxygenation, 233
 funding responsibilities, 220
 milestones in Swedish health care, 214
 Ministry of Health and Social Affairs,215
 National Board of Health and Welfare
 allocation of medical posts, 220
 CABG and PTCA, 225,226-227
 ESRD policy, 231,232
 establishment, 214
 mammography screening, 234
 medical devices regulation, 221 -222
 perinatology conference, 232-233
 quality assurance, 222
 National Board of Occupational Safety and Health, 215
 National Corporation of Swedish Pharmacies, 215

366 Health Care Technology and Its Assessment in Eight Countries

- National Drug Institution, 215
 - National Environmental Protection Board, 215
 - National Food Administration, 215
 - National Health Insurance Act, 213
 - National Institute of Radiation Protection, 215
 - National Pharmaceutical Board, 221
 - National Register of Laparoscopic Surgery, 230
 - National Social Insurance Board, 215
 - population, GDP per capita, and health care spending, 2, 3
 - Public Health Institute, 213
 - Social Research Council, 220
 - summary, 234-236
 - Swedish Council on Technology Assessment in Health Care
 - back pain, 223
 - funding responsibilities, 220
 - hypertension, 223
 - mental health technology study, 224
 - MRI assessment, 229
 - preoperative investigations in elective surgery, 223
 - radiation treatment of cancer, 223
 - responsibilities, 222-224
 - Swedish Planning and Rationalization Institute, 215
 - consensus conferences, 224
 - MRI assessment, 229
 - responsibilities, 224-225
- T**
- Thermography
 - Canada, 73
 - United States, 284
- U**
- Ultrasound
 - Canada, 75
 - United Kingdom. *See also* International comparisons
 - Audit Commission, 248,257
 - Cancer Coordinating Committee Breast Screening Sub-Committee, 270
 - case studies
 - breast cancer screening, 13,269-270
 - coronary artery disease, 258-260
 - end-stage renal disease, 264-267
 - laparoscopic surgery, 262-264
 - medical imaging (CT and MRI), 260-262
 - neonatal intensive care, 12,267-269
 - Central Research and Development Committee, 249-250
 - Clinical Advisory Group, 268-269
 - Clinical Standards Advisory Group, 257
 - Cochrane Centre, 250
 - Committee on the Review of Medicines, 252
 - Committee on the Safety of Medicine, 252
 - community health councils, 248
 - Coordinating Committee on Clinical Application of NMR
 - Imaging, 261-262
 - Department of Health
 - hemodialysis costs, 266
 - laparoscopic surgery policy, 263-264
 - medical equipment regulation, 253
 - pharmaceutical firm profitability assessment, 252
 - prescribing analysis and cost data, 253
 - prescription drug limited list, 252-253
 - provider location control, 254
 - “Report of an Independent Review of Specialist Services in London,” 259
 - responsibilities, 245
 - District Health Authorities, 245
 - Family Health Service Authorities, 245
 - Forrest Report, 269-270
 - government and political structure, 241
 - health care system
 - England, 244
 - funding, 243,247
 - health care purchaser-provider relationship, 245
 - health policy, 245
 - impact of reforms, 248-249
 - principles, 243-244
 - purchasing chain, 245-246
 - reforms planned, 246-248
 - Wales, Scotland, and Northern Ireland, 244
 - health care technology assessment
 - assessment entities, 256-257
 - health care technology controls
 - control of use, 255
 - medical equipment regulation, 253-254
 - national policy development, 249-250
 - NHS Supplies Authority, 254
 - pharmaceuticals regulation, 250-253
 - placement of services, 254-255
 - private sector and consumers role, 255-256
 - provider location control, 254
 - utilization and quality control, 255
 - Health of the Nation program, 245
 - health status of the population
 - causes of death, 242
 - health care expenditure, 242
 - patient’s charter, 243,245,255
 - targets for health improvement, 242-243
 - House of Commons Health Committee report, 268

- House of Lords Select Committee on Science and Technology, 249-250
- infant mortality, 3, 242
- Joint Subcommittee and Standing Maternity and Midwifery Advisory Committee, 267
- King's Fund, 257
 - consensus conference on CABG, 259
 - Consensus Statement on CT scanners, 261
- life expectancy, 4
- medical audit, 257
- Medical Research Council
 - role, 256-257
- Medicines Act, 252
- National Audit Office, 248,254,268
- National Health Service
 - patient's charter, 243,245,255
- National Health Services Act, 244
- National Perinatal Epidemiology Unit, 268
- NHS and Community Care Act, 244,245
- NHS Management Executive, 244
- NHS trusts, 246,248
- population, GDP per capita, and health care spending, 2, 3
- Public Expenditure Survey Committee, 246
- Regional Health Authorities, 245
- Royal College of Physicians, 267-268
- Sheldon report on neonatal intensive care, 267
- Standing Group on Health Technology, 250
- Standing Medical Advisory Committees, 256-257
- summary, 271-272
- Trial for the Early Detection of Breast Cancer, 270
- University of York CT user guide, 261
- Wolfson Foundation, 264
- United States. *See also* International comparisons
 - Agency for Health Care Policy and Research
 - clinical practice guidelines, 294
 - funding sources, 293
 - guidelines for diagnosing and managing unstable angina, 306
 - Office of Health Technology Assessment, 292, 297-298, 300,305,309,310,312-313
 - patient outcomes research teams, 295-297
 - aging of the population, 279
 - American Academy of Pediatrics, 300
 - American Cancer Society
 - breast cancer screening, 322,323
 - American College of Cardiology, 306
 - American College of Physicians, 300
 - American College of Radiology
 - breast cancer screening, 322-323
 - American Herit Association, 306
 - American Medical Association, 292
 - Diagnostic and Therapeutic Technology Assessment program, 300-301
 - American Society of Transplant Surgeons, 317
 - Blue Cross/Blue Shield, 277
 - Medical Advisory Panel, 301
 - Medical Necessity Program, 301
 - MRI benefits, 309-310
 - Technology, Evaluation, and Coverage program, 301
 - Breast and Cervical Cancer Mortality Prevention Act, 321
 - Breast Cancer Detection Demonstration Project, 322
 - case studies
 - breast cancer screening, 13,321-323
 - coronary artery disease, 304-307
 - end-stage renal disease, 315-318
 - laparoscopic surgery, 9, 311-315
 - medical imaging (CT and MRI), 307-311
 - neonatal intensive care, 318-321
 - Center for Research Dissemination Liaison, 297
 - certificate-of-need program, 285, 307, 308, 310
 - Civilian Health and Medical Program for the Uniformed Services, 278
 - Clinical Efficacy Assessment Program, 300
 - Committee on Perinatal Health, 318
 - Council on Health Care Technology, 292
 - defensive medicine, 279
 - Department of Veterans Affairs
 - hospitals and outpatient clinics, 278
 - Food, Drug, and Cosmetic Act, 282
 - Medical Device Amendments, 283,308,309
 - Food and Drug Administration, 281-283
 - Framingham Heart Study, 306
 - General Accounting Office
 - mammography machines, 321-322
 - Health Care Financing Administration
 - ESRD payments, 316,317-318
 - health care system
 - delivery system, 277
 - description, 276-277
 - federal and local governments as providers, 278
 - health care expenditures, 278-279
 - health insurance, 277-278
 - number of physicians, 277
 - recent reform efforts, 279-280
 - health care technology assessment
 - databases, 303-304
 - federal efforts, 291-300
 - private sector assessments, 300-302
 - recent trends, 302-303
 - health care technology controls
 - health maintenance organizations, 289

368 Health Care Technology and Its Assessment in Eight Countries

- health planning and, 285
 - managed care, 289-291
 - medical device marketing approval, 283-285
 - payment, coverage, and utilization controls, 286-289
 - pharmaceuticals marketing review, 281-283
 - physician profiling, 290-291
 - preferred provider organizations, 289
 - utilization management, 289-290, 291
 - health status of the population, 276
 - Indian Health Service, 278
 - infant mortality rate, 3, 318
 - Institute of Medicine, 292,343
 - end-stage renal disease study, 315
 - Investigational Devices Exemption, 284
 - Kaiser Permanente
 - autologous bone marrow transplantation, 302
 - life expectancy, 4
 - Maine Medical Assessment Foundation, 290
 - Mammography Quality Standards Act, 322
 - Medicaid, 277,278
 - Medicare
 - capital equipment payments, 288
 - coverage description, 277, 278
 - DRG system, 288,303
 - end-stage renal disease, 315-318
 - ESRD payments policy, 316-317
 - “experimental” defined, 287
 - Health Care Financing Administration
 - coverage standard, 287-288
 - mammography coverage, 322
 - new technology and, 286-287
 - physician payments, 289
 - Prospective Payment Assessment Commission, 288,315,318
 - prospective payment system, 288,306-307, 310
 - “usual, customary, and reasonable” method of physician payment, 289
 - Medicare Catastrophic Coverage Act, 322
 - National Cancer Advisory Board, 323
 - National Cancer Institute
 - autologous bone marrow transplantation, 301-302
 - breast cancer screening consensus development conference, 322
 - budget, 281
 - mammography machines, 321
 - National Center for Health Care Technology, 292
 - National Council on Health Care Technology, 292
 - National Health Planning and Resources Development Act, 285,307,310
 - National Heart, Lung and Blood Institute
 - budget, 281
 - Coronary Artery Surgery Study, 305
 - National Institute for Allergy and Infectious Diseases
 - budget, 281
 - National Institute of Diabetes and Digestive and Kidney Disorders, 315
 - National Institutes of Health
 - clinical indications for MRI, 309
 - consensus conferences, 224, 299, 305
 - Consensus Development Conference, 315
 - funding, 280-281
 - National Organ Transplant Act, 316
 - National Research Council, 343
 - off-label uses of drugs, 284-285
 - Office of Technology Assessment, 343
 - Omnibus Budget Reconciliation Act, 322
 - Oregon Medicaid proposal, 300,303
 - Orphan Drug Act, 283,317
 - overview, 275-276
 - peer review organizations, 290
 - pharmaceutical and medical device industries, 281
 - population, GDP per capita, and health care spending, 2, 3
 - professional standards review organizations, 290, 308
 - Renal Data System, 315
 - research and development, 280-281
 - Safe Medical Devices Act, 284
 - Social Security Act, 287
 - Social Security Act Amendments, 316
 - Social Security disability payments for ESRD, 7
 - summary, 324-325
 - United Network for Organ Sharing, 315
 - University Hospital Consortium, 302
 - U.S. Preventive Services Task Force, 299-300
 - Veterans Administration
 - CABG benefits, 226
 - CABG randomized trial, 305
- V
- Vineberg procedure, 304
- W
- WHO. See World Health Organization
 - World Health Organization
 - CABG recommendations, 226
- X
- X-ray imaging
 - Germany, 155
- Z
- Zidovudine, 38